LPTX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own LPTX shares is 56, representing 40.3% of the company's common stock.

KNOTT DAVID M JR, in the last quarter, reduced its stake in LPTX by -33.58% restricting it's holding to 557.94 thousand shares of worth nearly $190.00K. RENAISSANCE TECHNOLOGIES LLC also lessened -50.83% of the LPTX shares from its portfolio, reducing its holding to 455.2 thousand shares of worth $155.00K. PLATINUM INVESTMENT MANAGEMENT LTD also shunned LPTX shares holding by -80.09% last quarter which brought its holding to 264.41 thousand shares worth $89.90K.

As per its latest 13F filing, 683 CAPITAL MANAGEMENT, LLC increased its stake in LPTX by 1.82% in the last quarter. The institutional holder raised its holding to 2.8 million shares having worth more than $952.00K. PRICE T ROWE ASSOCIATES INC /MD/ also added 100% more shares of LPTX to its portfolio, raising its holding to 1.54 million shares of worth $523.00K. KEY CLIENT FIDUCIARY ADVISORS, LLC also increased its LPTX shares holding by 13.82% which brought its holding to 1.54 million shares worth $522.18K.

The insider with the most stakes in LPTX is BeiGene, Ltd. , 10 percent owner at the company. Additionally, LPTX stock is highly held by 10 percent owner PERCEPTIVE ADVISORS LLC and CFO, GC, Treasurer & Secretary ONSI DOUGLAS E among others.

Company executives, directors, and other insiders own 17.29% percent of Leap Therapeutics, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which LPTX insiders have sold stock, totaling 0 shares. Insiders that have sold shares include .

There have been 0 transaction(s) during the past 6-months in which Leap Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 0 Leap Therapeutics, Inc. shares are held by insiders, which represents about 17.29% of LPTX stock.

LPTX 10 percent owner, BeiGene, Ltd. holds the largest portfolio of the company's shares. LPTX shares owned by BeiGene, total nearly 7.35 million.

683 CAPITAL MANAGEMENT, LLC is the largest institutional owner in LPTX which holds 2.8 million shares worth $952.00K or 2.16% of the total LPTX shares outstanding followed by PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 1.54 million shares representing 1.19% of the LPTX ownership. KEY CLIENT FIDUCIARY ADVISORS, LLC is the third largest stakeholder with 1.54 million shares or 1.19% of the ownership worth more than $522.18K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the LPTX is concerned, it is a stock which is optionable.

Number of LPTX shares short is 3.21M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 38.32M shares of LPTX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, LPTX has 23.66M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for LPTX is 2.38.